Blood Marker Could Predict Risk of Hip Fracture In Older Men
The chemokine protein CXCL9, which promotes bone-resorbing osteoclast formation, is linked with a higher risk of hip fracture in men.
No such difference was seen women.
Early interventions targeting CXCL9 or CXCL9-CXCR3 signaling could be beneficial in preventing hip fractures in older men.
Bone health requires a balanced activity of various bone cell types including bone-forming osteoblasts and bone-resorbing osteoclasts. Bone loss occurs when osteoclasts dominate without adequate bone formation to compensate. In new research published in the Journal of Bone and Mineral Research, elevated blood levels of a certain chemokine, or small signaling protein, that promotes osteoclast formation were linked with a higher risk of hip fracture in men.
The study included 55 men and 119 women who had experienced a hip fracture an average of 6.3 years after their blood was collected. The participants were matched individually to controls who did not develop hip fractures.
Investigators observed higher blood levels of the chemokine CXCL9 in the pre-fracture blood samples of men with subsequent hip fractures compared with their non-fracture controls. No such difference was seen women.
“The unexpected difference in the results between men and women in our study may be explained by how changes in sex hormone levels during aging could influence the level and effects of CXCL9 differently in older men and women,” explained corresponding author Woon-Puay Koh, MBBS, PhD, from the National University of Singapore (NUS).
“Our findings open the exciting possibility that early interventions targeting CXCL9 or CXCL9-CXCR3 signalling could be beneficial in preventing hip fractures in older men,” added co-corresponding author Christoph Winkler, PhD, also from NUS.
Journal of Bone and Mineral Research
CXCL9 predicts the risk of osteoporotic hip fracture in a prospective cohort of Chinese men